Point72 Asia (Singapore) Pte. Ltd. Protagonist Therapeutics, Inc Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 2,699 shares of PTGX stock, worth $110,766. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,699
Previous 14,556
81.46%
Holding current value
$110,766
Previous $504 Million
75.92%
% of portfolio
0.02%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
246Shares Held
56.5MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$241 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$236 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$223 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$173 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$131 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.01B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...